CHENGZHI(SZ:000990)2024-04-16 08:14Financial Performance - The company's operating revenue for Q1 2024 was ¥2,721,207,122.73, a decrease of 19.14% compared to ¥3,365,397,917.36 in the same period last year[5] - Net profit attributable to shareholders was ¥154,051,640.00, a significant increase of 370.36% from a loss of ¥56,979,827.62 in the previous year[5] - Basic and diluted earnings per share were both ¥0.1268, compared to a loss of ¥0.0469 per share in the previous year, reflecting a 370.36% increase[5] - The company’s total comprehensive income for the period was CNY 177,722,326.51, compared to a loss of CNY -29,142,455.84 in the previous period[57] - The company's net profit for the current period is CNY 177,664,926.49, representing a 706.86% increase compared to the previous period[64] - Operating profit increased to CNY 224,627,337.39, a significant rise of 854.82% compared to the previous period[64] - Total profit for the current period is CNY 224,481,465.01, reflecting a 708.98% increase from the previous period[64] Cash Flow - The net cash flow from operating activities reached ¥610,996,153.03, marking a 403.06% improvement from a negative cash flow of ¥201,611,413.38 in the same period last year[5] - Cash flow from financing activities totaled ¥1,767,618,522.46, an increase of 30.91% from ¥1,350,299,146.64, mainly due to repayment of bank loans[50] - The cash and cash equivalents at the end of the period amounted to CNY 2,287,253,428.64, an increase from CNY 1,618,763,342.80[58] - Cash flow from operating activities generated a net amount of ¥610.99 million, a substantial increase from a negative cash flow of ¥201.61 million in the previous year[73] Investment Activities - Cash paid for investments surged to ¥1,320,241,035.63, up 428.09% from ¥250,003,362.03, primarily due to increased scale of current financial investments[50] - The company has made an additional investment of CNY 460 million in the Huade New Opportunities Fund, with no further updates as of the reporting period[66] - The company reported a decrease in employee compensation payable by 41.51% to CNY 60,727,841.72, down from CNY 103,823,030.14[63] - The company reported a net cash outflow from investing activities of CNY -494,650,192.71, compared to a net inflow of CNY 415,384,554.77 in the previous period[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥25,962,273,173.77, a slight increase of 0.85% from ¥25,743,376,064.65 at the end of the previous year[5] - The company's total liabilities amount to CNY 7,314,080,516.92, slightly up from CNY 7,280,190,487.54 in the previous period[71] - The total equity attributable to shareholders of the parent company is CNY 17,808,604,102.56, an increase from CNY 17,650,708,059.42 in the previous period[71] Projects and Developments - The company is progressing with the POE project, having completed the development of the technology package and is preparing for the review meeting[11] - The new integrated propylene value chain project in Nanjing has a total investment of ¥1.05 billion, with the main construction completed and auxiliary works ongoing[13] - The company is advancing the IPO preparation for its subsidiary, Chengzhi Yonghua, with due diligence work ongoing[26] - The company plans to invest ¥350 million in the construction of multifunctional and raw material drug workshops in Yingtan, Jiangxi, with the first phase nearing trial operation[53] - The subsidiary Yunnan Hanmeng Pharmaceutical Co., Ltd. has completed the application for industrial hemp planting permits and has begun trial production[52] Other Income and Expenses - Other income for Q1 2024 increased to ¥13,599,915.20, up 69.38% from ¥8,029,171.29 in Q1 2023, primarily due to increased government subsidies[49] - Investment income improved to -¥10,172,789.44, a 51.26% reduction in losses compared to -¥20,873,459.40 in the same period last year, mainly due to reduced losses from associated companies[49] - The company achieved a significant reduction in financial expenses, with interest expenses decreasing to ¥38.50 million from ¥46.57 million, reflecting better debt management[72] - The company reported a decrease in sales expenses to ¥24.00 million from ¥28.86 million, showing improved cost management[72]